BACKGROUND: Mutations in TNFRSF13B, the gene encoding transmembrane activator and calcium modulator cyclophilin ligand interactor (TACI), are found in 10% of patients with common variable immunodeficiency. However, the most commonly detected mutation is the heterozygous change C104R, which is also found in 0.5% to 1% of healthy subjects. The contribution of the C104R mutation to the B-cell defects observed in patients with common variable immunodeficiency therefore remains unclear. OBJECTIVE: We sought to define the functional consequences of the C104R mutation on B-cell function. METHODS: We performed in vitro studies of TACI C104R expression and signaling. A knock-in mouse with the equivalent mutation murine TACI (mTACI) C76R was generated as a physiologically relevant model of human disease. We examined homozygous and heterozygous C76R mutant mice alongside wild-type littermates and studied specific B-cell lineages and antibody responses to T cell-independent and T cell-dependent challenge. RESULTS: C104R expression and ligand binding are significantly diminished when the mutant protein is expressed in 293T cells or in patients' cell lines. This leads to defective nuclear factor κB activation, which is proportionally restored by reintroduction of wild-type TACI. Mice heterozygous and homozygous for mTACI C76R exhibit significant B-cell dysfunction with splenomegaly, marginal zone B-cell expansion, diminished immunoglobulin production and serological responses to T cell-independent antigen, and abnormal immunoglobulin synthesis. CONCLUSIONS: These data show that the C104R mutation and its murine equivalent, C76R, can significantly disrupt TACI function, probably through haploinsufficiency. Furthermore, the heterozygous C76R mutation alone is sufficient to disturb B-cell function with lymphoproliferation and immunoglobulin production defects.
BACKGROUND: Mutations in TNFRSF13B, the gene encoding transmembrane activator and calcium modulator cyclophilin ligand interactor (TACI), are found in 10% of patients with common variable immunodeficiency. However, the most commonly detected mutation is the heterozygous change C104R, which is also found in 0.5% to 1% of healthy subjects. The contribution of the C104R mutation to the B-cell defects observed in patients with common variable immunodeficiency therefore remains unclear. OBJECTIVE: We sought to define the functional consequences of the C104R mutation on B-cell function. METHODS: We performed in vitro studies of TACI C104R expression and signaling. A knock-in mouse with the equivalent mutation murine TACI (mTACI) C76R was generated as a physiologically relevant model of human disease. We examined homozygous and heterozygous C76R mutant mice alongside wild-type littermates and studied specific B-cell lineages and antibody responses to T cell-independent and T cell-dependent challenge. RESULTS: C104R expression and ligand binding are significantly diminished when the mutant protein is expressed in 293T cells or in patients' cell lines. This leads to defective nuclear factor κB activation, which is proportionally restored by reintroduction of wild-type TACI. Mice heterozygous and homozygous for mTACI C76R exhibit significant B-cell dysfunction with splenomegaly, marginal zone B-cell expansion, diminished immunoglobulin production and serological responses to T cell-independent antigen, and abnormal immunoglobulin synthesis. CONCLUSIONS: These data show that the C104R mutation and its murine equivalent, C76R, can significantly disrupt TACI function, probably through haploinsufficiency. Furthermore, the heterozygous C76R mutation alone is sufficient to disturb B-cell function with lymphoproliferation and immunoglobulin production defects.
Authors: Yolanda Garcia-Carmona; Montserrat Cols; Adrian T Ting; Lin Radigan; Frank J Yuk; Li Zhang; Andrea Cerutti; Charlotte Cunningham-Rundles Journal: Blood Date: 2015-01-28 Impact factor: 22.113
Authors: Wikke Koopmans; See-Tarn Woon; Anna E S Brooks; P Rod Dunbar; Peter Browett; Rohan Ameratunga Journal: J Clin Immunol Date: 2012-09-15 Impact factor: 8.317
Authors: Haifa H Jabara; John J Lee; Erin Janssen; Sumana Ullas; Kyriaki Liadaki; Lilit Garibyan; Halli Benson; Tatyana Sannikova; Richard Bram; Lennart Hammarstrom; Anthony C Cruz; Richard Siegel; John Manis; Richard Malley; Raif S Geha Journal: J Allergy Clin Immunol Date: 2016-09-05 Impact factor: 10.793
Authors: Rohan Ameratunga; Klaus Lehnert; See-Tarn Woon; David Gillis; Vanessa L Bryant; Charlotte A Slade; Richard Steele Journal: Clin Rev Allergy Immunol Date: 2018-04 Impact factor: 8.667
Authors: Rohan Ameratunga; See-Tarn Woon; Vanessa L Bryant; Richard Steele; Charlotte Slade; Euphemia Yee Leung; Klaus Lehnert Journal: Front Immunol Date: 2018-01-26 Impact factor: 7.561
Authors: Rohan Ameratunga; Wikke Koopmans; See-Tarn Woon; Euphemia Leung; Klaus Lehnert; Charlotte A Slade; Jessica C Tempany; Anselm Enders; Richard Steele; Peter Browett; Philip D Hodgkin; Vanessa L Bryant Journal: Clin Transl Immunology Date: 2017-10-20